Clinical Trial Update: Efficacy and Safety of Sacubitril/Valsartan Compared With Enalapril on Morbidity, Mortality, and NT-proBNP Change in Patients With CCC [Phase 4]

View source ↗

Summary

Phase 4 trial comparing sacubitril/valsartan to enalapril in patients with Chagas disease-related cardiomyopathy, assessing morbidity, mortality, and NT-proBNP …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chagas Disease
• Heart Failure

Drugs mentioned

• Enalapril (enalapril)
• Sacubitril/Valsartan (sacubitril/valsartan)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chagas Disease, Heart Failure | Phase 4 | Status: COMPLETED